
    
      The two effective and non-cross resistant regimens, VTD and MPT, will be applied sequentially
      to the patients with multiple myeloma who are not transplant candidates. This would be
      expected to result in maximal tumor control, and thus, in maximal survival benefit,
      equivalent to high dose therapy with autologous transplantation in younger population
    
  